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Abstract 
Biomedical accelerators used in radiotherapy are equipped with detector arrays which are commonly used to obtain the 
image of patient position during the treatment session. These devices use both kilovolt and megavolt x-ray beams. The 
advantage of EPID (Electronic Portal Imaging Device) megavolt panels is the correlation of the measured signal with 
the calibrated dose. The EPID gives a possibility to verify delivered dose. The aim of the study is to answer the question 
whether EPID can be useful as a tool for interfraction QC (quality control) of dose and geometry repeatability. 
The EPID system has been calibrated according to the manufacturer's recommendations to obtain a signal and dose 
values correlation. Initially, the uncertainty of the EPID matrix measurement was estimated. According to that, the 
detecting sensitivity of two parameters was checked: discrepancies between the planned and measured dose and field 
geometry variance. Moreover, the linearity of measured signal-dose function was evaluated. 
In the second part of the work, an analysis of several dose distributions was performed. In this study, the analysis of 
clinical cases was limited to stereotactic dynamic radiotherapy. Fluence maps were obtained as a result of the dose 
distribution measurements with the EPID during treatment sessions. The compatibility of fluence maps was analyzed 
using the gamma index. The fluence map acquired during the first fraction was the reference one. The obtained results 
show that EPID system can be used for interfraction control of dose and geometry repeatability. 
Key words: EPID; gamma index; fluence map. 
 
Introduction 
Electronic portal devices were proposed for clinical practice at 
the turn of the 20th and 21st centuries. They were dedicated for 
the verification of patient setup during the therapeutic session 
[1,2], as well as for the dose estimation [3-8]. Initially, only a 
megavolt beam was used both for planar images and 
volumetric reconstructions CBCT (Cone Beam Computed 
Tomography). The advantage for CBCT reconstructions is the 
minimized amount of artifacts from metal objects, compared to 
the number of artifacts obtained with the use of kilovolt beam. 
The disadvantages are the worse tissue differentiation and the 
higher dose delivered to the patient during imaging while 
comparing with kilovolt beams [9]. In addition, dedicated 
software was developed to reduce the metal artifacts in 
acquired images that are produced by high-density materials 
[10-12]. Till now, this kind of software is available only for 
computed tomography scanners (CT). It is highly probable that 
this type of software will be implemented for OBI (On-Board 
Imaging with kilovolt x-ray beam), which is used in IGRT 
(Image Guided Radiation Therapy) techniques. Thus, the 
question appears if megavolt detectors integrated with the 
therapeutic units still have a future. Certainly, those detectors 
can be used for dose measurement during the therapeutic 
sessions. EPID is commonly used to compare the calculated 
and measured fluence map. It should be noted that such 
verification procedures are usually done with a patient's 
absence and are a part of dynamic plans QA [13,14]. Such 
measurements do not give the information on dose distribution 
in patient body. The reconstruction of patient dose absorbed in 
a single fraction requires dedicated software [15-21]. The 
proposed proceeding would allow correlating the EPID signal 
collected during the irradiation with the dose in patient body. 
This would enable EPID dosimetry without new software and 
hardware usage. 
 
Bereitgestellt von  Uniwersytet Slaski - University of Silesia - Silesian University | Heruntergeladen  13.01.20 11:55   UTC
Aleksandra Klimas et al: EPID – a useful interfraction QC tool  Pol J Med Phys Eng 2019;25(4):221-228 
 222 
Material and method 
The study was performed with aS1200 EPID devices integrated 
with TrueBeam and Edge accelerators (Varian Medical 
Systems, Palo Alto, CA, USA). The active panel area is 
43.0 × 43.0 cm2, with a resolution of 1280 × 1280 pixels and 
with a maximum recording speed of 20 sets of frames per 
second [22]. During the acceptance tests and commissioning 
measurements, all EPID matrices were calibrated following the 
manufacturer's recommended procedures [23]. 
 
Phantom set-up 
In all measurements, the tissue-like phantom EASY CUBE 
Body Module S (Lap GmbH Laser Applikationen, Lueneburg, 
Germany) was used. Additionally, culture flask (Falcon, 
25 cm2, https://en.vwr.com) was filled with water and placed 
inside the EASY CUBE phantom. Their location can be clearly 
visible in both kilovolt and megavolt imaging (Figure 1). First, 
the phantom CT imaging was performed using data acquisition 
and image reconstruction protocols as used clinically for 
typical head scans. Imaging data were imported into the 
Eclipse v.13.6 TPS (Treatment Planning System) (Varian 




The treatment field was set up to 15 × 15 cm2 at the isocenter 
located on the flask base. For all photon energies X-6 MV, X-
15 MV and X-10 MV-FFF the dose distributions were made 
with 0.5, 1.0, 2.0 and 7.0 Gy dose specified at isocenter. For 
the filtered and filtered free beams, the dose rate of 
600 MU/min and 2400  MU/min were used respectively. 
Additionally, for all treatment plans the dose at isocenter was 
measured with 30013 Farmer ionization chamber and T10001 





EPID method sensitivity 
The repeatability of the EPID measurements was checked by 
irradiating four times the EPID matrix for all the mentioned 
energies and doses. Fluence maps of the 15 × 15 cm2 of the 
field were acquired in the "Integrated Image" measurement 
mode [23,24]. For the further analysis a 2 × 2 cm2 region of 
interest with its center at the isocenter was selected. The 
agreement of the four measured fluence maps was assessed in 
the area of interest. The first fluence map was the reference 
one. The evaluation was conducted with the usage of the 
gamma index, calculated with the criteria of ∆d = 0.5% and 
DTA = 0.5 mm [25]. 
 Four fluence maps acquired for given energy and dose were 
the independent group of data. Further, those data were the 
base for the nonparametric tests. 
 
Linearity 
In the region of interest, the mean value of the acquired signals 
was calculated. The unit of the calculated and measured 
fluence maps in Varian system is CU (Calibration Units) [24]. 
The linearity between the number of CU and the dose was 
checked for all selected beams. Four arbitrary dose values were 
chosen: 0.5, 1.0, 2.0 and 7.0 Gy. 
 
Dose and geometry change sensitivity 
For the X-6 MV beam, the sensitivity for the dose changes was 
tested. The doses of 0.45, 0.50 and 0.55 Gy at the isocenter for 
15 × 15 cm2 field were prescribed. For these doses the fluence 
maps were acquired. To assess the differences between the 
fluence maps of the three doses the gamma index in the area of 
2 × 2 cm2 was calculated. Three pairs of gamma criteria were 
established: (i) ∆d = 0.5% and DTA = 0.5 mm, (ii) ∆d = 2.0% 
and DTA = 2.0 mm, and (iii) ∆d = 4.0% and DTA = 4.0 mm. 
To determine the statistical significance the nonparametric tests 
method for independent samples (Mann-Whitney U test) was 
performed. 
 
a)  b)  c)  
 
Figure 1. Imaging of the culture flasks in different x-ray beams: kilovoltage (a), megavoltage (b) and digital reconstruction (DRR) obtained 
from kilovoltage computed tomography (c). 
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Table 1. Percentage values of the analyzed field that meet the gamma ≤ 1 criteria of ∆d = 0.5% and DTA = 0.5 mm, mean values of CU, 
standard deviation and uncertainty (bold) calculated for three beam energies and four tested doses. 
Beam 
0.5 Gy  1.0 Gy  2.0 Gy  7.0 Gy 
%S CU (mean) 
SD 
(CU) ∆ [%] 
 %S CU (mean) 
SD 
(CU) ∆ [%] 
 %S CU (mean) 
SD 
(CU) ∆ [%] 
 %S CU (mean) 
SD 
(CU) ∆ [%] 
X-6MV 98.9 0.103 0.007 7.3  100.0 0.204 0.005 2.7  100.0 0.406 0.002 0.5  100.0 1.430 0.007 0.5 
X-15MV 98.9 0.132 0.000 0.2  99.2 0.265 0.001 0.3  99.3 0.531 0.001 0.2  99.3 1.861 0.004 0.2 
FFF-X-10MV 99.7 0.129 0.001 0.4  99.8 0.258 0.001 0.4  99.8 0.517 0.002 0.4  99.8 1.812 0.007 0.4 
 
Once more the X-6 MV beam and isocentric 15 × 15 cm2 field 
were used for geometry tests. In order to estimate the ability to 
find a geometric error, the phantom was shifted in the lateral 
and longitudinal axes by 3.0 mm. The phantom in reference 
and the shifted position was irradiated and the fluence maps 
were acquired. Differences between the proper and shifted 
fluence maps were evaluated with the gamma index in 
2 × 2  cm2 area within four pairs of criteria: (i) ∆d = 0.5% and 
DTA = 0.5 mm, (ii) ∆d = 2.0% and DTA = 2.0 mm, (iii) 
∆d = 4.0% and DTA = 4.0 mm and (iv) ∆d = 5.0% and 
DTA = 5.0 mm. 
 Then, the received data were statistically analyzed using 
nonparametric tests for independent samples. Results of the 
dosimetric and geometric tests were the base of the null 
hypothesis stated. The numerical values of fluence maps were 
the analyzed data sets. There were 8 pairs of sets for different 
dosimetric and geometrical conditions. The null hypothesis 
stated: if at least 98% of the analyzed field meets the gamma 
≤ 1 condition for ∆d = 2.0% and DTA = 2.0 mm criteria, then 
the sets are not identical. 
 
Analysis of clinical cases 
The practical usefulness of the EPID matrix as dosimetry 
system was proved by measurements of the fluence maps. The 
fluence maps were acquired for 19 fractionated stereotactic 
plans (VMAT or IMRT). Two measurements were made for 16 
patients and three measurements were made for 3 patients. In 
total, 75 fluence maps were compared and analyzed. For all 87 
comparisons were done. Each treatment was realized with the 
EPID device in mode enabling the measurement of radiation 
passing through the patient body. The first measured fluence 
map was the reference one. The next fraction maps were 
compared to the first one. The gamma index was determined in 
two ways for (i) ∆d = 0.5% and DTA = 0.5 mm, (ii) ∆d = 2.0% 
and DTA = 2.0 mm. For both sets of criteria the mean values of 
gamma index were calculated. 
 Moreover, each measured fluence map was exported to 
Statistica v. 12 (https://www.statsoft.pl) and using Mann-
Whitney U test the comparison was made to check whether 
these sets are identical. The significance criterion was p-value 




EPID method sensitivity 
Table 1 shows the percentage of the analyzed field with the 
gamma coefficient less or equal than one for the criteria: 
∆d = 0.5% and DTA = 0.5 mm and the average values of the 
CU from the area of interest defined as 2.0 x 2.0 cm2 with the 
value of the standard deviation. For every energy and dose 
used in the study, the values of percentage uncertainty (∆) were 
calculated. The mean value of the %S calculated for all energy 
and doses equals 99.1% with the average measurement 
uncertainty of 1.1%. This value was obtained as the average 
value of all uncertainties (bold numbers in Table 1). 
 The results of nonparametric tests for independent groups of 
data showed no statistically significant differences. However, it 
should be noted that for low energies and doses the 
measurement uncertainty is greater. 
 
Linearity  
The graph of a signal measured by the EPID matrix during 
irradiation as the function of the dose for photon radiation: 
X-6 MV, X-15 MV, and X-10 MV-FFF is shown in Figure 2. 
The correlation coefficient R2 = 0.9999 shows a linear 
dependency of the CU value and the dose value. Performed 
measurements and calculations confirmed strong linear 
dependency between the dose and the detector signal, which 
allows using this device to assess radiation doses. 
 
Figure 2. The measured signal as a function of the dose in the 
range from 0.5 to 7.0 Gy for photon beams: X-6 MV and X-15 MV 
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Dose and geometry change sensitivity 
To evaluate the dose change sensitivity the CU numbers in 
2.0 x 2.0 cm2 central area for 0.50 Gy, 0.45 Gy and 0.55 Gy 
were used. Differences between pairs of fluence maps were 
calculated using the gamma index. The analyzed data show a 
significant statistical difference. The results for three different 
pairs of criteria are presented in Table 2. The tested 10% 
difference of dose significantly affects the %S that meets the 
criterion of the gamma index for and ∆d = 0.5% and 
DTA = 0.5 mm. For assumed criteria, less than 10% of the 
analyzed area meets the condition of gamma value ≤ 1. On this 
basis, one can state that a change in dose by 10% can be 
confirmed by measurements made with EPID matrix. Results 
indicate that the EPID detector is able to assess the value of 
delivered dose. 
 To find a geometric error using fluence map measurement, 
the 3.0 mm phantom shifts were applied. Table 3 presents the 
differences between shifted and non-shifted fluence maps 
calculated with four different gamma criteria. Pairs of fluence 
maps were acquired for three dose values. The results of 
geometry change analysis show that for 0.5% and 0.5 mm 
criterion only 78% of the analyzed field meets the acceptance 
conditions. Therefore, it can be said that a 3.0 mm shift of the 
phantom causes the differences in the analyzed signal sets. The 
results were confirmed by statistical tests. 
 Table 4 presents the results of comparison of measured 
fluence maps acquired for three different dose values and two 
field geometries. Also the calculation of p-value for the 
Pearson Ch2 and Ch2 NW tests is included. The performed tests 
authorize the rejection of the null hypothesis (Pearson's Ch2: 
p = 0.00468; Ch2 NW: p = 0.00114), and therefore one can say 
that these conditions are dependent. It means that, when the 
dose differences between measured fluence maps are less than 
2.0% and 2.0 mm for 98% of the analyzed field, then the maps 








%S gamma ≤ 1 
p-value ∆d[%]/DTA[mm] ∆d[%]/DTA[mm] ∆d[%]/DTA[mm] 
0.5/0.5 2.0/2.0 4.0/4.0 
0.45 vs. 0.50 7.6 26.6 31.9 0.000 
0.45 vs. 0.55 2.5 24.4 32.2 0.000 
0.50 vs. 0.55 8.1 27.1 35.1 0.000 
 
Table 3. The percentage value of the surface of the analyzed field (%S) with gamma index ≤ 1 for given doses and different gamma criteria 
for field shift = 3.0 mm. 
Dose 
[Gy] 
%S gamma ≤ 1 
p-value ∆d[%]/DTA[mm] ∆d[%]/DTA[mm] ∆d[%]/DTA[mm] ∆d[%]/DTA[mm] 
0.5/0.5 2.0/2.0 4.0/4.0 5.0/5.0 
0.45 75.4 92.0 98.2 99.2 0.000 
0.50 78.6 91.8 98.3 99.2 0.000 
0.55 78.7 91.2 98.3 99.4 0.000 
 
Table 4. The percentage value of the surface of the analyzed field (%S) with gamma index ≤ 1 for given doses and shifts for different gamma 
criteria and results of nonparametric tests. 
Shift Dose [Gy] 
%S gamma ≤ 1 
p-value 
gamma ≤ 1  
for 98.0% of field 
(2.0%/2.0mm) 
Identical 
fluence maps ∆d[%]/DTA[mm] ∆d[%]/DTA[mm] ∆d[%]/DTA[mm] 
0.5/0.5 2.0/2.0 4.0/4.0 
N 0.50 100.0 100.0 100.0 0.626 Y Y 
Y 0.50 78.6 91.8 98.3 0.000 N N 
N 0.45/0.50 7.6 26.6 31.9 0.000 N N 
Y 0.55 78.7 91.2 98.3 0.000 N N 
N 0.55 100.0 100.0 100.0 0.091 Y Y 
N 0.45/0.55 2.5 24.4 32.2 0.000 N N 
N 0.50/0.55 8.1 27.1 32.4 0.000 N N 
N 0.45 100.0 100.0 100.0 0.464 Y Y 
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Figure 3. Gamma index analysis for an example patient for Field 2. The yellow selection presents acceptable results for ∆d = 2.0% and 
DTA = 2.0 mm and rejected one for ∆d = 0.5% and DTA = 0.5 mm. The blue selection presents 92.0% of analyzed area that meets the 
gamma criteria ∆d = 0.5% and DTA = 0.5 mm. Graphics show: (A) first fraction fluence map, (B) second fraction fluence map, (C) blended, 
(D) profiles along the collimator axes, (E) histogram of dose difference. 
 
Analysis of clinical cases 
Figure 3 shows example patient results of gamma index 
calculation for the comparison of two fractions. It is shown, 
that 92% of the analyzed area meets the gamma index ≤ 1 for 
the criteria of ∆d = 0.5% and DTA = 0.5 mm. However, the 
change in DTA value to 2.0 mm and ∆d value to 2.0% caused 
that 100% of the analyzed area meets the gamma ≤ 1 condition. 
 In the case, Mann-Whitney U statistics show that for Field 2 
p-value is equal to 0.9440, which means that there is no 
significant statistical difference between two fluence maps. 
Therefore, one can conclude that the patient was irradiated with 
Field 2 repeatedly these days. 
 All the plans were analyzed the same way what gives 87 
comparisons of measured fluence maps. Results of patient-
specific measurements present the values of the gamma index 
showing similarity of fluence maps measured during 
subsequent therapeutic sessions. The maps were compared 
each other using two criteria: (i) ∆d = 0.5% and DTA = 0.5 mm 
and (ii) ∆d = 2.0% and DTA = 2.0 mm. The second evaluation 
of the identity of the maps was the Mann-Whitney U test. The 
results are shown in Table 5. If gamma index ≤ 1 for at least 
98% of the analyzed area with criteria of ∆d = 2.0 % and 
DTA = 2.0 mm, then two sets can be considered as identical. 
This condition is fulfilled in 73 out of 87 analyzed cases. 
 
Discussion 
Dynamic radiotherapy techniques (VMAT and IMRT) require 
pre-treatment dosimetry verification. The measurement of the 
fluence map only allows checking if the calculated collimator 
leaf motion, linac gantry movement, dose rate changes, etc. can 
be properly realized. It can be also a kind of absolute dosimetry 
after fulfilling several conditions. For calibration purposes, 
simultaneous measurements with an ionization chamber and 
the EPID matrix are necessary. It allows correlating the dose in 
a phantom with the EPID signal. Also dose distribution from 
the patient plan has to be converted to the phantom with 
ionization chamber [26,27]. But it is still not in-vivo dosimetry. 
The another QA procedure is patient set-up control. The 
present workflow usually separates the dosimetric verification 
and patient position check. 
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Table 5. Results of patient-specific measurements and Mann-Whitney U test. 
# patient 




%S gamma ≤ 1 
p-value ∆d[%]/DTA[mm] ∆d[%]/DTA[mm] 
  
∆d[%]/DTA[mm] ∆d[%]/DTA[mm] 
0.5/0.5 2.0/2.0 0.5/0.5 2.0/2.0 
1   (2 fx)   11   (2 fx)   
field_1 51.7 100.0 0.888 field_1 88.9 100.0 0.890 
field_2 62.1 100.0 0.871 field_2 91.6 100.0 0.890 
field_3 78.9 100.0 0.806 field_3 90.2 100.0 0.890 
2   (2 fx)   field_4 92.2 100.0 0.888 
field_1 40.8 97.6 0.330 field_5 82.5 96.3 0.007 
field_2 43.4 99.7 0.771 field_6 84.3 95.2 0.011 
field_3 70.1 100.0 0.967 field_7 82.2 96.2 0.008 
3   (2 fx)   field_8 81.2 95.4 0.005 
field_1 99.9 100.0 1.000 12   (2 fx)   
field_2 99.4 100.0 0.754 field_1 96.5 100.0 0.808 
field_3 98.7 100.0 0.890 field_2 96.1 100.0 0.694 
4   (2 fx)   field_3 93.1 100.0 0.655 
field_1 100.0 100.0 0.890 13   (2 fx)   
field_2 99.9 100.0 0.751 field_1 99.4 100.0 0.736 
field_3 100.0 100.0 0.961 field_2 99.6 100.0 0.888 
field_4 100.0 100.0 0.888 field_3 98.6 100.0 0.888 
5   (2 fx)   field_4 99.3 100.0 0.838 
field_1 99.9 100.0 0.888 14   (2 fx)   
field_2 99.9 100.0 0.888 field_1 99.6 100.0 0.909 
6   (2 fx)   field_2 99.7 100.0 0.288 
field_1 69.3 88.1 0.001 field_3 99.7 100.0 0.669 
field_2 69.6 88.3 0.005 field_4 99.7 100.0 0.874 
field_3 72.0 88.6 0.001 15   (3 fx)   
7   (2 fx)   field_1   2->1 98.8 100.0 0.899 
field_1 99.4 100.0 0.870 field_1   3->2 97.8 100.0 0.792 
field_2 98.6 100.0 0.891 field_2   2->1 98.6 100.0 0.794 
field_3 99.7 100.0 0.885 field_3   3->2 92.0 98.3 0.944 
field_4 99.5 100.0 0.871 field_3   2->1 98.4 100.0 0.888 
field_5 99.5 100.0 0.891 field_3   3->2 97.9 100.0 0.791 
field_6 99.7 100.0 0.867 16   (2 fx)   
8   (3 fx)   field_1 88.8 99.6 0.625 
field_7  2->1 99.7 100.0 0.885 field_2 88.5 99.3 0.398 
field_7  3->1 99.8 100.0 0.873 field_3 95.2 99.9 0.786 
field_8  2->1 100.0 100.0 0.895 field_4 95.6 99.2 0.431 
field_8  3->1 99.2 100.0 0.884 17   (2 fx)   
field_9  2->1 99.7 100.0 0.896 field_1 99.2 100.0 0.624 
field_9  3->1 99.8 100.0 0.876 field_2 98.5 100.0 0.817 
field_10  2->1 99.3 100.0 0.890 field_3 99.1 100.0 0.888 
field_10  3->1 99.9 100.0 0.895 field_4 99.0 100.0 0.798 
field_11  2->1 99.6 100.0 0.875 field_5 98.8 100.0 0.888 
field_11  3->1 99.7 100.0 0.884 18   (2 fx)   
field_12  2->1 100.0 100.0 0.873 field_1 98.9 100.0 0.988 
field_12  3->1 99.0 100.0 0.891 field_2 99.0 100.0 0.931 
9   (2 fx)   field_3 98.8 100.0 0.745 
field_5 88.9 96.8 0.888 field_4 98.6 100.0 0.687 
field_6 89.6 97.5 0.021 field_5 99.5 100.0 0.735 
10   (3 fx)   19   (2 fx)   
field_1    2->1 49.1 92.6 0.012 field_1 50.7 100.0 0.882 
field_1    3->1 66.7 92.2 0.006 field_2 47.3 100.0 0.992 
field_2    2->1 48.4 92.1 0.009 field_3 48.8 100.0 0.888 
field_2    3->1 64.3 91.3 0.000 field_4 46.0 100.0 0.830 
field_3    2->1 39.7 90.5 0.046 
  
field_3    3->1 53.3 88.5 0.006 
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An alternative method of dose measurement can be usage of 
external detector matrix and dose reconstruction software 
[28,29]. This processing can be made to assess the compliance 
of the calculated and delivered dose. Nevertheless, almost 
every biomedical accelerator (C-arm type) is equipped with 
EPID array which is an integral element of modern therapeutic 
units. Thus in the present work the EPID matrix was used. 
 This work is an attempt to present a method of using the 
EPID matrix for the measurements of dose and geometry 
changes. At this point it should be highlighted that in present 
work the measured dose is not compared with the dose 
calculated in treatment planning system. The proposed method 
allows fluence maps measuring in subsequent sessions with the 
presence of the patient and comparing them with the reference 
one. It is recommended to utilize the fluence map acquired for 
the first fraction as the reference data set. As before the 
required step is patient position verification before each 
session. 
 The measurements confirm that simulated dose change 
causes the expected change in the measured maps. It should be 
noted, that the displacement of structures relative to the 
planned position also causes differences in measured fluence 
maps. It can also be stated that the arrays of the aS1200 EPID 
detectors are very stable measuring matrices, with a 
measurement uncertainty of 1.1%. 
This work is not about the agreement between measured and 
calculated dose, but about the repeatability of measurements. 
The EPID arrays show the linearity of the read signal with the 
radiation dose. In the tested dose range from 0.5 to 7.0 Gy, the 
R2 correlation coefficient is equal to one. Analysis of clinical 
cases indicates that repetitive dose was delivered to the patients 
undergoing radiosurgical treatment and no shifts in the 
irradiated area were detected. 
 Radiosurgical patients are very precisely immobilized so 
mobility during the therapeutic session is negligible. This is 
confirmed by imaging performed during each therapeutic 
session with the OBI device. The proposed method can be used 
to assess the repeatability of radiation therapy, both in 
assessing the value of the delivered dose and its location. The 
further test of the method will be continued for fractionated 
radiotherapy and with extracranial locations. 
 
Conclusions 
The performed measurements, calculations, and analysis 
indicate that the EPID detector matrix can be used for 
dosimetric and geometric QC in dynamic stereotactic radiation 
therapy. This technique could be applied both for dose and 
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